{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:07:59Z","timestamp":1787317679818,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.vaccine.2021.08.003","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T20:06:58Z","timestamp":1628885218000},"page":"5650-5657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Single-vial filovirus glycoprotein vaccines: Biophysical characteristics and immunogenicity after co-lyophilization with adjuvant"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3997-6997","authenticated-orcid":false,"given":"Kendall B.","family":"Preston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri Ann S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7118-9803","authenticated-orcid":false,"given":"Albert","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3054-9163","authenticated-orcid":false,"given":"Taylor E.","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4684-0158","authenticated-orcid":false,"given":"Michael M.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Feliciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Yalley-Ogunro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne Andersen","family":"Elyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9879-3031","authenticated-orcid":false,"given":"Oreola","family":"Donini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel T.","family":"Lehrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore W.","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2021.08.003_b0005","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ijpharm.2016.08.022","article-title":"A Design of Experiment approach to predict product and process parameters for a spray dried influenza vaccine","volume":"511","author":"Kanojia","year":"2016","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.003_b0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","article-title":"Vaccine instability in the cold chain: Mechanisms, analysis and formulation strategies","volume":"42","author":"Kumru","year":"2014","journal-title":"Biologicals"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.003_b0015","first-page":"1","article-title":"Formulation, stability, and delivery of live attenuated vaccines for human use","volume":"16","author":"Burke","year":"1999","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.003_b0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/153834402320882593","article-title":"Lyophilization and the thermostability of vaccines","volume":"1","author":"Rexroad","year":"2002","journal-title":"Cell Preserv Technol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.003_b0025","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1586\/erv.09.20","article-title":"Opportunities and challenges of developing thermostable vaccines","volume":"8","author":"Chen","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.003_b0030","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-018-1254-2","article-title":"Stability of Vaccines","volume":"20","author":"Dumpa","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.vaccine.2021.08.003_b0035","unstructured":"Sanofi Pasteur. Package Insert - SHINGRIX. US Food Drug Adm 2019. https:\/\/www.fda.gov\/media\/108597\/download."},{"key":"10.1016\/j.vaccine.2021.08.003_b0040","article-title":"Summary of Stability Data for Licensed Vaccines","author":"PATH","year":"2012","journal-title":"Seattle, WA"},{"issue":"30","key":"10.1016\/j.vaccine.2021.08.003_b0045","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1016\/j.vaccine.2014.05.037","article-title":"Freeze-thaw stress of Alhydrogel\u00ae alone is sufficient to reduce the immunogenicity of a recombinant hepatitis B vaccine containing native antigen","volume":"32","author":"Clapp","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.003_b0050","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/jps.22284","article-title":"Vaccines with aluminum-containing adjuvants: Optimizing vaccine efficacy and thermal stability","volume":"100","author":"Clapp","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2021.08.003_b0055","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1016\/j.vaccine.2018.10.023","article-title":"Physical and chemical changes in AlhydrogelTM damaged by freezing","volume":"36","author":"Kurz\u0105tkowski","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.003_b0060","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ejpb.2013.03.029","article-title":"Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization","volume":"85","author":"Hassett","year":"2013","journal-title":"Eur J Pharm Biopharm"},{"issue":"40","key":"10.1016\/j.vaccine.2021.08.003_b0065","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1016\/j.vaccine.2018.08.059","article-title":"Thermal stability and epitope integrity of a lyophilized ricin toxin subunit vaccine","volume":"36","author":"Westfall","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.003_b0070","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jps.24295","article-title":"Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid a adjuvants","volume":"104","author":"Hassett","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2021.08.003_b0075","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejpb.2015.05.009","article-title":"Development of a highly thermostable, adjuvanted human papillomavirus vaccine","volume":"94","author":"Hassett","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.vaccine.2021.08.003_b0080","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejpb.2019.01.019","article-title":"Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide","volume":"136","author":"Chisholm","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"10.1016\/j.vaccine.2021.08.003_b0085","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.xphs.2017.02.024","article-title":"Feasibility of Freeze-Drying Oil-in-Water Emulsion Adjuvants and Subunit Proteins to Enable Single-Vial Vaccine Drug Products","volume":"106","author":"Iyer","year":"2017","journal-title":"J Pharm Sci"},{"issue":"1-2","key":"10.1016\/j.vaccine.2021.08.003_b0090","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijpharm.2016.02.047","article-title":"Freeze-drying of emulsified systems: A review","volume":"503","author":"Morais","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.vaccine.2021.08.003_b0095","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.vaccine.2005.01.133","article-title":"Sucrose fatty acid sulphate esters as novel vaccine adjuvant","volume":"24","author":"Hilgers","year":"2006","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2021.08.003_b0100","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.vaccine.2004.07.021","article-title":"Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition","volume":"23","author":"Blom","year":"2004","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2021.08.003_b0105","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1016\/j.xphs.2020.09.011","article-title":"Preservation of Quaternary Structure in Thermostable, Lyophilized Filovirus Glycoprotein Vaccines: A Search for Stability-Indicating Assays","volume":"109","author":"Preston","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2021.08.003_b0110","unstructured":"U.S. Food and Drug Administration. First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response n.d. https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health (accessed January 16, 2020)."},{"issue":"6","key":"10.1016\/j.vaccine.2021.08.003_b0115","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/infdis\/jiv532","article-title":"Stability of a Vesicular Stomatitis Virus-Vectored Ebola Vaccine","volume":"213","author":"Arnemo","year":"2016","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.003_b0120","doi-asserted-by":"crossref","first-page":"e001955","DOI":"10.1136\/bmjgh-2019-001955","article-title":"Forty-two years of responding to Ebola virus outbreaks in Sub-Saharan Africa: A review","volume":"5","author":"Rugarabamu","year":"2020","journal-title":"BMJ Glob Heal"},{"key":"10.1016\/j.vaccine.2021.08.003_b0125","doi-asserted-by":"crossref","unstructured":"Jacob ST, Crozier I, Fischer WA, Hewlett A, Kraft CS, Vega MA de La, et al. Ebola virus disease. vol. 6. Springer US; 2020. https:\/\/doi.org\/10.1038\/s41572-020-0147-3.","DOI":"10.1038\/s41572-020-0147-3"},{"key":"10.1016\/j.vaccine.2021.08.003_b0130","doi-asserted-by":"crossref","unstructured":"Lehrer AT, Wong TAS, Lieberman MM, Humphreys T, Clements DE, Bakken RR, et al. Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice. Vaccine 2018;36:3090\u2013100. https:\/\/doi.org\/10.1016\/j.vaccine.2017.01.068.","DOI":"10.1016\/j.vaccine.2017.01.068"},{"key":"10.1016\/j.vaccine.2021.08.003_b0135","article-title":"Vaccine Adjuvants","author":"Fox","year":"2017","journal-title":"Methods and Protocols."},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.003_b0140","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pep.2005.01.016","article-title":"Protein production by auto-induction in high density shaking cultures","volume":"41","author":"Studier","year":"2005","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2021.08.003_b0145","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2016.06.017","article-title":"DLS and zeta potential - What they are and what they are not?","volume":"235","author":"Bhattacharjee","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2021.08.003_b0150","first-page":"44","article-title":"Methods for characterization of nanoparticles","author":"Kumar","year":"2017","journal-title":"Adv Nanomedicine Deliv Ther Nucleic Acids"},{"issue":"17","key":"10.1016\/j.vaccine.2021.08.003_b0155","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.2217\/nnm.14.193","article-title":"The impact of size on particulate vaccine adjuvants","volume":"9","author":"Shah","year":"2014","journal-title":"Nanomedicine"},{"issue":"7","key":"10.1016\/j.vaccine.2021.08.003_b0160","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1080\/21645515.2015.1046660","article-title":"Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants","volume":"11","author":"Iyer","year":"2015","journal-title":"Hum Vaccin"},{"issue":"15","key":"10.1016\/j.vaccine.2021.08.003_b0165","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.vaccine.2019.02.048","article-title":"Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice","volume":"37","author":"Wui","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.003_b0170","doi-asserted-by":"crossref","unstructured":"Mabrouk MT, Huang W, Deng B, Li-purcell N, Seffouh A, Ortega J, et al. Lyophilized , antigen-bound liposomes with reduced MPLA and enhanced thermostability 2020;589. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119843.","DOI":"10.1016\/j.ijpharm.2020.119843"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.003_b0175","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-020-03253-1","article-title":"The thermostability of the RTS, S\/AS01 malaria vaccine can be increased by co-lyophilizing RTS, S and AS01","volume":"19","author":"Fortpied","year":"2020","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2021.08.003_b0180","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jconrel.2013.12.025","article-title":"Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization","volume":"177","author":"Orr","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2021.08.003_b0185","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.2147\/IJN.S159839","article-title":"Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach","volume":"13","author":"Kramer","year":"2018","journal-title":"Int J Nanomedicine"},{"issue":"8","key":"10.1016\/j.vaccine.2021.08.003_b0190","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1128\/CVI.00107-16","article-title":"Human survivors of disease outbreaks caused by Ebola or Marburg virus exhibit cross-reactive and long-lived antibody responses","volume":"23","author":"Natesan","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2021.08.003_b0195","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01907-20","article-title":"Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization","volume":"95","author":"Wang","year":"2021","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.08.003_b0200","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/jps.22458","article-title":"Trehalose: Current use and future applications","volume":"100","author":"Ohtake","year":"2011","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.vaccine.2021.08.003_b0205","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0006-3495(96)79407-9","article-title":"Is trehalose special for preserving dry biomaterials?","volume":"71","author":"Crowe","year":"1996","journal-title":"Biophys J"},{"issue":"15","key":"10.1016\/j.vaccine.2021.08.003_b0210","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.addr.2006.09.017","article-title":"Freeze-drying of nanoparticles: Formulation, process and storage considerations","volume":"58","author":"Abdelwahed","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"issue":"1-2","key":"10.1016\/j.vaccine.2021.08.003_b0215","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijpharm.2007.08.011","article-title":"The properties of bufadienolides-loaded nano-emulsion and submicro-emulsion during lyophilization","volume":"349","author":"Li","year":"2008","journal-title":"Int J Pharm"},{"issue":"12","key":"10.1016\/j.vaccine.2021.08.003_b0220","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1002\/jps.21786","article-title":"Cryoprotectants for freeze drying of drug nano-suspensions: Effect of freezing rate","volume":"98","author":"Lee","year":"2009","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.003_b0225","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1006\/cryo.2000.2244","article-title":"Literature review: Supplemented phase diagram of the trehalose-water binary mixture","volume":"40","author":"Chen","year":"2000","journal-title":"Cryobiology"},{"key":"10.1016\/j.vaccine.2021.08.003_b0230","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4615-0549-5","author":"Nail","year":"2002","journal-title":"Development and Manufacture of Protein Pharmaceuticals."},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.003_b0235","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nbt0595-493","article-title":"Aggregation of a Lyophilized Pharmaceutical Protein, Recombinant Human Albumin: Effect of Moisture and Stabilization by Excipients","volume":"13","author":"Costantino","year":"1995","journal-title":"Nat Biotechnol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21010021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21010021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:02:08Z","timestamp":1759402928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21010021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":47,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0264410X21010021"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.003","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-vial filovirus glycoprotein vaccines: Biophysical characteristics and immunogenicity after co-lyophilization with adjuvant","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}